HC Wainwright & Co. analyst Yi Chen maintains Glaukos (NYSE:GKOS) with a Buy and raises the p

JP Morgan analyst Allen Gong maintains Glaukos (NYSE:GKOS) with a Overweight and raises the price

Citigroup analyst Joanne Wuensch maintains Glaukos (NYSE:GKOS) with a Buy and raises the price ta

Glaukos raised its 2026 sales forecast to $775 million to $785 million and set a preliminary 2027 ta

Gainers Glaukos (NYSE:GKOS) shares rose 30.8% to $237.26 during Thursday's regular session. The

Truist Securities analyst Richard Newitter maintains Glaukos (NYSE:GKOS) with a Buy and raises th

Stocks rallied on strong earnings and raised guidance, led by Huntington Ingalls, Porch, Teladoc and

Wells Fargo analyst Larry Biegelsen maintains Glaukos (NYSE:GKOS) with a Overweight and raises th

Piper Sandler analyst Adam Maeder reiterates Glaukos (NYSE:GKOS) with a Overweight and raises the

Glaukos Corp (NYSE:GKOS) on Wednesday reported better-than-expected third-quarter financial results

Glaukos beat Q3 estimates, raised FY26 sales guidance to $775M-$785M, and shares jumped 17.4%; analy

Stifel analyst Tom Stephan maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target f

BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target

Analysts raised targets for Microsoft, VF, Glaukos, Hilton, AxoGen and Brinker; Renasant’s target wa

Gainers Mesoblast (NASDAQ:MESO) stock rose 16.2% to $15.57 during Thursday's pre-market session

Needham analyst David Saxon maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target

Shares of Glaukos Corp (NYSE:GKOS) rose sharply in pre-market trading after the company reported bet

Glaukos surged 17.4% premarket after strong Q3 results and raised FY26 sales guidance; INLF, NCPL an

Glaukos shares jump 17.61% after hours as third-quarter earnings beat estimates and the company rais

Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript

Glaukos (GKOS) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Esti

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter e

Glaukos NYSE: GKOS reported record third-quarter consolidated net sales of $211 million, up 58% from

Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 20.4% to $0.34 during Wednesday's after-market

Glaukos (NYSE:GKOS) raises FY2026 sales outlook from $680.000 million-$700.000 million to $775.000 m

Glaukos (NYSE:GKOS) reported quarterly earnings of $0.47 per share which beat the analyst consensus

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

State of Alaska Department of Revenue lowered its stake in Glaukos Corporation (NYSE: GKOS) by 48.6%

GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher

BTIG analyst Ryan Zimmerman maintains Glaukos (NYSE:GKOS) with a Buy and raises the price target

Glaukos is transitioning from a single-product reimbursement story to a diversified ophthalmic pharm

GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rig

Ophthalmic pharmaceutical and medical technology firm Glaukos Corporation (NYSE:GKOS) reported succe

Glaukos reports positive Phase 4 results for its iDose TR therapy, demonstrating superior efficacy o

Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

Glaukos Corporation (NYSE:GKOS) reported three-year trial results for its non-invasive keratoconus t

Glaukos reports positive three-year Epioxa study results and secures an exclusive license for RevOps

Development targeted for the treatment of neovascular age-related macular degeneration (nAMD), diabe

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

Glaukos said on Wednesday patients treated with its late-stage eye disease therapy maintained improv

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

U.S. stocks fell, while BKV surged 9.2% on an equipment contract announcement; Penguin Solutions led

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical

Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 2.33% on an annualized bas

Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad p

Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 1.4% on an annualized basi

Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 3.9% on an annualized basi

Glaukos (NYSE:GKOS) has outperformed the market over the past 5 years by 15.09% on an annualized bas